Tumor targeting with a selective gelatinase inhibitor

被引:485
作者
Koivunen, E
Arap, W
Valtanen, H
Rainisalo, A
Medina, OP
Heikkilä, P
Kantor, C
Gahmberg, CG
Salo, T
Konttinen, YT
Sorsa, T
Ruoslahti, E
Pasqualini, R
机构
[1] Univ Helsinki, Dept Biosci, Div Biochem, FIN-00014 Helsinki, Finland
[2] Burnham Inst, La Jolla, CA 92037 USA
[3] Univ Helsinki, Dept Periodontol, FIN-00014 Helsinki, Finland
[4] Univ Oulu, Dept Diagnost & Oral Med, FIN-90401 Oulu, Finland
[5] Univ Helsinki, Dept Anat, FIN-00014 Helsinki, Finland
关键词
phage display; matrix metalloproteinase; tumor targeting; angiogenesis; cancer therapy;
D O I
10.1038/11703
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Several lines of evidence suggest that tumor growth, angiogenesis, and metastasis are dependent on matrix metalloproteinase (MMP) activity, However, the lack of inhibitors specific for the type IV collagenase/gelatinase family of MMPs has thus far prevented the selective targeting of MMP-2 (gelatinase A) and MMP-9 (gelatinase B) for therapeutic intervention in cancer, Here, we describe the isolation of specific gelatinase inhibitors from phage display peptide libraries. We show that cyclic peptides containing the sequence HWGF are potent and selective inhibitors of MMP-2 and MMP-9 but not of several other MMP family members, Our prototype synthetic peptide, CTTHWGFTLC, inhibits the migration of human endothelial cells and tumor cells, Moreover, it prevents tumor growth and invasion in animal models and improves survival of mice bearing human tumors. Finally, we show that CTTHWGFTLC-displaying phage specifically target angiogenic blood vessels in vivo. Selective gelatinase inhibitors may prove useful in tumor targeting and anticancer therapies.
引用
收藏
页码:768 / 774
页数:7
相关论文
共 52 条
  • [1] Anderson IC, 1996, CANCER RES, V56, P715
  • [2] Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model
    Arap, W
    Pasqualini, R
    Ruoslahti, E
    [J]. SCIENCE, 1998, 279 (5349) : 377 - 380
  • [3] Arap Wadih, 1998, Current Opinion in Oncology, V10, P560, DOI 10.1097/00001622-199811000-00014
  • [4] Recent advances in matrix metalloproteinase inhibitor research
    Beckett, RP
    Davidson, AH
    Drummond, AH
    Huxley, P
    Whittaker, M
    [J]. DRUG DISCOVERY TODAY, 1996, 1 (01) : 16 - 26
  • [5] PROTEOLYTIC REMODELING OF EXTRACELLULAR-MATRIX
    BIRKEDALHANSEN, H
    [J]. CURRENT OPINION IN CELL BIOLOGY, 1995, 7 (05) : 728 - 735
  • [6] Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity
    Brooks, PC
    Silletti, S
    von Schalscha, TL
    Friedlander, M
    Cheresh, DA
    [J]. CELL, 1998, 92 (03) : 391 - 400
  • [7] Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3
    Brooks, PC
    Stromblad, S
    Sanders, LC
    vonSchalscha, TL
    Aimes, RT
    StetlerStevenson, WG
    Quigley, JP
    Cheresh, DA
    [J]. CELL, 1996, 85 (05) : 683 - 693
  • [8] DAVIES B, 1993, CANCER RES, V53, P2087
  • [9] DOMINGO GJ, 1995, INT J PEPT PROT RES, V46, P79
  • [10] Eccles SA, 1996, CANCER RES, V56, P2815